STI

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coggins, C
Right arrow Articles by Ellertson, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coggins, C
Right arrow Articles by Ellertson, C
Sexually Transmitted Infections 76:480-483 (2000)
© 2000 BMJ Publishing Group

Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide

C Coggins1, K Blanchard1, F Alvarez2, V Brache2, E Weisberg3, P H Kilmarx4, M Lacarra5, R Massai6, D Mishell, Jr5, A Salvatierra6, P Witwatwongwana7, C Elias8, C Ellertson1

1 The Population Council, New York, USA
2 Asociacion Dominicana Pro-Bienestar de la Familia, Santo Domingo, Dominican Republic
3 Sydney Centre for Reproductive Health Research, Department of Obstetrics and Gynaecology, University of Sydney, Sydney, Australia
4 Centers for Disease Control and Prevention, Atlanta, USA; The HIV/AIDS Collaboration, Chiang Rai, Thailand
5 University of Southern California, Los Angeles, USA
6 Instituto Chileno de Medicina Reproductiva, Santiago, Chile
7 Chiang Rai Hospital, Chiang Rai, Thailand
8 The Population Council, Bangkok, Thailand

Kelly Blanchard, Population Council, One Dag Hammarskjold Plaza, New York, NY 10017, USA kblanchard{at}pcjoburg.org.za

Objective: We sought to determine the safety and acceptability of vaginal gel formulation PC-503 among low risk, abstinent women. The active ingredient was 2% pharmaceutical grade lambda carrageenan, a sulphated polymer that is generally recognised as safe by the US Food and Drug Administration.

Methods: 35 women in five sites applied 5 ml of the PC-503 gel vaginally once a day for 7 days while abstaining from sexual intercourse. Visual vaginal examinations were performed on days 1, 4, and 8. STI testing and vaginal pool Gram stain preparations were done on days 1 and 8. Participants were asked about product acceptability.

Results: 34 of the 35 women enrolled completed 7 days' use. Following product use, five reported mild symptoms including "bladder fullness," "genital warmth," or discomfort, and lower abdominal pain, and one had moderate pale yellow cervical discharge. Using the Nugent criteria, three women had bacterial vaginosis (BV) before and after use; three had BV before but not after, and two had BV after but not before. Most of the women found PC-503 to be pleasant or neutral in feel and smell and considered extra lubrication to be an advantage; however, one third found it to be messy.

Conclusions: Vaginal use of PC-503 gel did not cause significant adverse effects in a small number of low risk, sexually abstinent women. Further testing in larger numbers of sexually active women is planned. A smaller volume of gel may be more acceptable to some women.

Key Words: microbicide; carrageenan




This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
R. F. Rando, S. Obara, M. C. Osterling, M. Mankowski, S. R. Miller, M. L. Ferguson, F. C. Krebs, B. Wigdahl, M. Labib, and H. Kokubo
Critical design features of phenyl carboxylate-containing polymer microbicides.
Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3081 - 3089.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
I. A. Scordi-Bello, A. Mosoian, C. He, Y. Chen, Y. Cheng, G. A. Jarvis, M. J. Keller, K. Hogarty, D. P. Waller, A. T. Profy, et al.
Candidate Sulfonated and Sulfated Topical Microbicides: Comparison of Anti-Human Immunodeficiency Virus Activities and Mechanisms of Action
Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3607 - 3615.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
G. N. Milligan, C.-F. Chu, C. G. Young, and L. R. Stanberry
Effect of Candidate Vaginally-Applied Microbicide Compounds on Recognition of Antigen by CD4+ and CD8+ T Lymphocytes
Biol Reprod, November 1, 2004; 71(5): 1638 - 1645.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
C. S. Dezzutti, V. N. James, A. Ramos, S. T. Sullivan, A. Siddig, T. J. Bush, L. A. Grohskopf, L. Paxton, S. Subbarao, and C. E. Hart
In Vitro Comparison of Topical Microbicides for Prevention of Human Immunodeficiency Virus Type 1 Transmission
Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3834 - 3844.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Public HealthHome page
M. E. Bentley, A. M. Fullem, E. E. Tolley, C. W. Kelly, N. Jogelkar, N. Srirak, L. Mwafulirwa, G. Khumalo-Sakutukwa, and D. D. Celentano
Acceptability of a Microbicide Among Women and Their Partners in a 4-Country Phase I Trial
Am J Public Health, July 1, 2004; 94(7): 1159 - 1164.
[Abstract] [Full Text] [PDF]


Home page
Sex. Transm. Infect.Home page
A Vandebosch, E Goetghebeur, G Ramjee, M Alary, V Ettiegne-Traore, V Chandeying, and L Van Damme
Acceptability of COL-1492, a vaginal gel, among sex workers in one Asian and three African cities
Sex. Transm. Inf., June 1, 2004; 80(3): 241 - 243.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2000 by the BMJ Publishing Group Ltd.